New combo therapy targets tough leukemia gene mutation
NCT ID NCT04874194
First seen Nov 03, 2025 · Last updated Apr 25, 2026 · Updated 14 times
Summary
This study tested two drugs, omacetaxine and venetoclax, in 24 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that returned or didn't respond to treatment and had a RUNX1 gene change. The goal was to find the best dose and see if the combination could help control the disease. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.